Immunocore (NASDAQ:IMCR) Posts Earnings Results, Misses Expectations By $0.15 EPS

Immunocore (NASDAQ:IMCR) announced its quarterly earnings results on Friday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.15), FiscalAI reports. Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%.

Immunocore Stock Performance

Shares of IMCR stock traded up $2.59 during trading on Friday, hitting $30.99. The company’s stock had a trading volume of 1,526,513 shares, compared to its average volume of 507,836. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. The company has a market cap of $1.60 billion, a PE ratio of -83.75 and a beta of 0.82. The business has a fifty day moving average of $31.64 and a 200-day moving average of $31.73. Immunocore has a 52 week low of $27.50 and a 52 week high of $40.71.

Analysts Set New Price Targets

IMCR has been the subject of several analyst reports. Mizuho increased their price objective on Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 3rd. JPMorgan Chase & Co. assumed coverage on Immunocore in a research report on Friday, August 21st. They set an “overweight” rating and a $50.00 target price on the stock. Morgan Stanley set a $43.00 price target on Immunocore in a report on Friday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $55.86.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.